Credit Suisse (SIX:CSGN) analyst Judah Frommer maintained a Hold rating on PTC Therapeutics (NASDAQ:PTCT) on Friday, setting a price target of $50, which is approximately 30.75% above the present share price of $38.24.
Frommer expects PTC (NASDAQ:PTC) Therapeutics to post earnings per share (EPS) of -$1.83 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in PTC Therapeutics, with an average price target of $55.6.
The analysts price targets range from a high of $70 to a low of $45.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $117.94 million and a net profit of -$98.05 million. The company's market cap is $2.69 billion.
According to TipRanks.com, Credit Suisse analyst Judah Frommer is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 20.2% and a 64.56% success rate.
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.